Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.865
+0.025 (0.65%)
Nov 10, 2026, 12:15 PM EST - Market open
Inventiva Revenue
Inventiva had revenue of 1.31M EUR in the half year ending June 30, 2026, a decrease of -52.23%. This brings the company's total for the last twelve months to 3.62M. In the year 2025, Inventiva had annual revenue of 7.93M, down -46.17%.
Revenue (ttm)
3.62M EUR
Revenue Growth
-46.17%
P/S Ratio
314.15
Revenue / Employee
41,632 EUR
Employees
87
Market Cap
887.22M USD
Revenue by Geography
- China 9.13M 99.2%
- France 69.00K 0.8%
Fiscal year ended Dec 31, 2024 See the full Inventiva breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.93M | -6.80M | -46.17% |
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | -4.39M | -30.61% |
| Dec 31, 2016 | 14.35M | 5.69M | 65.66% |
| Dec 31, 2015 | 8.66M | 2.36M | 37.55% |
| Dec 31, 2014 | 6.30M | 1.20M | 23.46% |
| Dec 31, 2013 | 5.10M | 5.06M | 10,977.18% |
| Dec 31, 2012 | 46.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Pharming Group | 386.75M |
| Syndax Pharmaceuticals | 289.68M |
| Monte Rosa Therapeutics | 70.33M |
| Immatics | 47.65M |
| City Therapeutics | 14.34M |
| Aktis Oncology | 10.06M |
| Odyssey Therapeutics | 99.00K |
IVA News
- 23 hours ago - Inventiva Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 5 days ago - Inventiva price target lowered to $14 from $24 at H.C. Wainwright - TheFly
- 4 weeks ago - Inventiva Slides: Corporate presentation - Filings
- 4 weeks ago - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - MarketBeat
- 4 weeks ago - Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 - GlobeNewsWire
- 5 weeks ago - Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test - MarketBeat
- 5 weeks ago - Inventiva price target raised to $18 from $13 at Truist - TheFly
- 5 weeks ago - Inventiva Transcript: Stifel 2026 Virtual Cardiometabolic Forum - Transcripts